Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains

Douglas G. Walker, Lih Fen Lue, Charles Howard Adler, Holly A. Shill, John Nathaniel Caviness, Marwan N. Sabbagh, Haruhiko Akiyama, Geidy E. Serrano, Lucia I. Sue, Thomas G. Beach

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Modifications of α-synuclein resulting in changes in its conformation are considered to be key pathological events for Lewy body diseases (LBD), which include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have previously described a histopathological Unified Staging System for LBD that classifies the spread of α-synuclein phosphorylated at serine 129 (pS129-α-synuclein) from olfactory bulb to brainstem or limbic regions, and finally neocortex. Lewy bodies and Lewy neurites are highly enriched in pS129-α-synuclein. Increased formation of pS129-α-synuclein changes its solubility properties enhancing its tendency to aggregate and disrupt normal function. As in vitro and animal studies have shown that inhibiting formation of pS129-α-synuclein can prevent toxic consequences, this has become one of the therapeutic targets for LBD. However, detailed biochemical descriptions of the changes in pS129-α-synuclein properties in diseased human brains are needed to further our understanding of how these might contribute to molecular pathogenesis. In this study, we used 130 separate brain samples from cingulate cortex (limbic cortex) and 131 from temporal cortex (neocortex) that had been staged according to our Unified Staging System to examine progressive changes in properties of pS129-α-synuclein with the formation of progressively more severe histological Lewy-type pathology. The brain samples from these staged cases had been separated into cytosol-enriched, membrane-enriched (detergent soluble) and insoluble (ureas/SDS soluble) fractions. We also characterized the nature and appearance of higher molecular weight forms of pS129-α-synuclein. The major species was the 16. kD monomeric form; this accumulated with increasing stage with a large increase in Stage IV samples. By comparing two brain regions, we showed higher accumulation of insoluble pS129-α-synuclein in cingulate cortex, where histological deposits occur first, than in temporal cortex in samples with advanced (stage IV) LB pathology.

Original languageEnglish (US)
Pages (from-to)190-204
Number of pages15
JournalExperimental Neurology
Volume240
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Synucleins
Serine
Brain
Lewy Body Disease
Neocortex
Gyrus Cinguli
Temporal Lobe
Pathology
Lewy Bodies
Poisons
Olfactory Bulb
Brain Diseases
Neurites
Detergents
Cytosol
Solubility
Brain Stem
Parkinson Disease
Urea

Keywords

  • Aggregation
  • Antibodies
  • Dementia with Lewy bodies
  • Fractionation
  • Incidental Lewy body disease
  • Parkinson's disease
  • Pathogenesis
  • Post-translational modification
  • Postmortem brain tissue
  • Western blots

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. / Walker, Douglas G.; Lue, Lih Fen; Adler, Charles Howard; Shill, Holly A.; Caviness, John Nathaniel; Sabbagh, Marwan N.; Akiyama, Haruhiko; Serrano, Geidy E.; Sue, Lucia I.; Beach, Thomas G.

In: Experimental Neurology, Vol. 240, No. 1, 02.2013, p. 190-204.

Research output: Contribution to journalArticle

Walker, Douglas G. ; Lue, Lih Fen ; Adler, Charles Howard ; Shill, Holly A. ; Caviness, John Nathaniel ; Sabbagh, Marwan N. ; Akiyama, Haruhiko ; Serrano, Geidy E. ; Sue, Lucia I. ; Beach, Thomas G. / Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. In: Experimental Neurology. 2013 ; Vol. 240, No. 1. pp. 190-204.
@article{ec85f6c4409e4233a6bea337bde1e1c9,
title = "Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains",
abstract = "Modifications of α-synuclein resulting in changes in its conformation are considered to be key pathological events for Lewy body diseases (LBD), which include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have previously described a histopathological Unified Staging System for LBD that classifies the spread of α-synuclein phosphorylated at serine 129 (pS129-α-synuclein) from olfactory bulb to brainstem or limbic regions, and finally neocortex. Lewy bodies and Lewy neurites are highly enriched in pS129-α-synuclein. Increased formation of pS129-α-synuclein changes its solubility properties enhancing its tendency to aggregate and disrupt normal function. As in vitro and animal studies have shown that inhibiting formation of pS129-α-synuclein can prevent toxic consequences, this has become one of the therapeutic targets for LBD. However, detailed biochemical descriptions of the changes in pS129-α-synuclein properties in diseased human brains are needed to further our understanding of how these might contribute to molecular pathogenesis. In this study, we used 130 separate brain samples from cingulate cortex (limbic cortex) and 131 from temporal cortex (neocortex) that had been staged according to our Unified Staging System to examine progressive changes in properties of pS129-α-synuclein with the formation of progressively more severe histological Lewy-type pathology. The brain samples from these staged cases had been separated into cytosol-enriched, membrane-enriched (detergent soluble) and insoluble (ureas/SDS soluble) fractions. We also characterized the nature and appearance of higher molecular weight forms of pS129-α-synuclein. The major species was the 16. kD monomeric form; this accumulated with increasing stage with a large increase in Stage IV samples. By comparing two brain regions, we showed higher accumulation of insoluble pS129-α-synuclein in cingulate cortex, where histological deposits occur first, than in temporal cortex in samples with advanced (stage IV) LB pathology.",
keywords = "Aggregation, Antibodies, Dementia with Lewy bodies, Fractionation, Incidental Lewy body disease, Parkinson's disease, Pathogenesis, Post-translational modification, Postmortem brain tissue, Western blots",
author = "Walker, {Douglas G.} and Lue, {Lih Fen} and Adler, {Charles Howard} and Shill, {Holly A.} and Caviness, {John Nathaniel} and Sabbagh, {Marwan N.} and Haruhiko Akiyama and Serrano, {Geidy E.} and Sue, {Lucia I.} and Beach, {Thomas G.}",
year = "2013",
month = "2",
doi = "10.1016/j.expneurol.2012.11.020",
language = "English (US)",
volume = "240",
pages = "190--204",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains

AU - Walker, Douglas G.

AU - Lue, Lih Fen

AU - Adler, Charles Howard

AU - Shill, Holly A.

AU - Caviness, John Nathaniel

AU - Sabbagh, Marwan N.

AU - Akiyama, Haruhiko

AU - Serrano, Geidy E.

AU - Sue, Lucia I.

AU - Beach, Thomas G.

PY - 2013/2

Y1 - 2013/2

N2 - Modifications of α-synuclein resulting in changes in its conformation are considered to be key pathological events for Lewy body diseases (LBD), which include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have previously described a histopathological Unified Staging System for LBD that classifies the spread of α-synuclein phosphorylated at serine 129 (pS129-α-synuclein) from olfactory bulb to brainstem or limbic regions, and finally neocortex. Lewy bodies and Lewy neurites are highly enriched in pS129-α-synuclein. Increased formation of pS129-α-synuclein changes its solubility properties enhancing its tendency to aggregate and disrupt normal function. As in vitro and animal studies have shown that inhibiting formation of pS129-α-synuclein can prevent toxic consequences, this has become one of the therapeutic targets for LBD. However, detailed biochemical descriptions of the changes in pS129-α-synuclein properties in diseased human brains are needed to further our understanding of how these might contribute to molecular pathogenesis. In this study, we used 130 separate brain samples from cingulate cortex (limbic cortex) and 131 from temporal cortex (neocortex) that had been staged according to our Unified Staging System to examine progressive changes in properties of pS129-α-synuclein with the formation of progressively more severe histological Lewy-type pathology. The brain samples from these staged cases had been separated into cytosol-enriched, membrane-enriched (detergent soluble) and insoluble (ureas/SDS soluble) fractions. We also characterized the nature and appearance of higher molecular weight forms of pS129-α-synuclein. The major species was the 16. kD monomeric form; this accumulated with increasing stage with a large increase in Stage IV samples. By comparing two brain regions, we showed higher accumulation of insoluble pS129-α-synuclein in cingulate cortex, where histological deposits occur first, than in temporal cortex in samples with advanced (stage IV) LB pathology.

AB - Modifications of α-synuclein resulting in changes in its conformation are considered to be key pathological events for Lewy body diseases (LBD), which include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have previously described a histopathological Unified Staging System for LBD that classifies the spread of α-synuclein phosphorylated at serine 129 (pS129-α-synuclein) from olfactory bulb to brainstem or limbic regions, and finally neocortex. Lewy bodies and Lewy neurites are highly enriched in pS129-α-synuclein. Increased formation of pS129-α-synuclein changes its solubility properties enhancing its tendency to aggregate and disrupt normal function. As in vitro and animal studies have shown that inhibiting formation of pS129-α-synuclein can prevent toxic consequences, this has become one of the therapeutic targets for LBD. However, detailed biochemical descriptions of the changes in pS129-α-synuclein properties in diseased human brains are needed to further our understanding of how these might contribute to molecular pathogenesis. In this study, we used 130 separate brain samples from cingulate cortex (limbic cortex) and 131 from temporal cortex (neocortex) that had been staged according to our Unified Staging System to examine progressive changes in properties of pS129-α-synuclein with the formation of progressively more severe histological Lewy-type pathology. The brain samples from these staged cases had been separated into cytosol-enriched, membrane-enriched (detergent soluble) and insoluble (ureas/SDS soluble) fractions. We also characterized the nature and appearance of higher molecular weight forms of pS129-α-synuclein. The major species was the 16. kD monomeric form; this accumulated with increasing stage with a large increase in Stage IV samples. By comparing two brain regions, we showed higher accumulation of insoluble pS129-α-synuclein in cingulate cortex, where histological deposits occur first, than in temporal cortex in samples with advanced (stage IV) LB pathology.

KW - Aggregation

KW - Antibodies

KW - Dementia with Lewy bodies

KW - Fractionation

KW - Incidental Lewy body disease

KW - Parkinson's disease

KW - Pathogenesis

KW - Post-translational modification

KW - Postmortem brain tissue

KW - Western blots

UR - http://www.scopus.com/inward/record.url?scp=84871489685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871489685&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2012.11.020

DO - 10.1016/j.expneurol.2012.11.020

M3 - Article

C2 - 23201181

AN - SCOPUS:84871489685

VL - 240

SP - 190

EP - 204

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -